Pralsetinib therapy shows high response in range of cancer patients with RET gene fusions
In a Phase I/II trial, cancer treatment with pralsetinib has produced high response rates in patients with RET gene fusions, regardless of tumor type, researchers reported on Aug.12, 2022 in Nature Medicine. “We’ve had an explosion in clinical next-generation sequencing that allows us to understand shared biomarkers across multiple tumor types, and this study was important to determine if RET fusions are […]
Recent Comments